Response and Toxicity to Topotecan in Sensitive Ovarian Cancer Cases with Small Residual Disease after First-Line Treatment with Carboplatinum and Paclitaxel
Articolo
Data di Pubblicazione:
2001
Citazione:
Response and Toxicity to Topotecan in Sensitive Ovarian Cancer
Cases with Small Residual Disease after First-Line Treatment
with Carboplatinum and Paclitaxel / G. Bolis, G. Scarfone, S. Tateo, G. Mangili, A. Villa, F. Parazzini. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 80:1(2001 Jan), pp. 13-15. [10.1006/gyno.2000.5995]
Abstract:
Objective. The objective of this open uncontrolled study was to
evaluate the toxicity and efficacy of topotecan in ovarian cancer
cases with microscopic small residual disease to a first-line treatment,
given as sequential treatment, including carboplatinum and
paclitaxel.
Methods. Inclusion criteria were laparotomically or laparoscopically
documented microscopic or macroscopic (<2 cm) residual
disease after first-line chemotherapy including carboplatinum plus
paclitaxel in patients with histologically documented epithelial
ovarian cancer FIGO stage III or IV at first diagnosis. All patients
had a response >50% after first-line treatment. Eligible patients
received 1.25 mg/m2/day of topotecan intravenously as a 30-min
infusion for 5 consecutive days every 21 days for four cycles. A
total of 38 women entered the study. Surgical “third-look” laparotomy
or laparoscopy was performed in patients without clinical/
instrumental evidence of progressive disease within 1 month from
the last topotecan administration.
Results. A complete response was observed in 10 cases (28.6%,
95% confidence interval, based on the Poisson’s approximation,
15.6 –59.5), a partial response in 1 (2.5%), progressive disease in 11
(31.4%) and no change/stable disease in 13. The median duration
of response was 8 months (range 5–20). The overall 1-year survival
after treatment was 82.8% (SE 6.4).
Conclusion. This study indicates that sequential therapy with
carboplatin plus paclitaxel followed by topotecan, all given at
standard doses, is feasible and provides favorable response
rates.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
G. Bolis, G. Scarfone, S. Tateo, G. Mangili, A. Villa, F. Parazzini
Link alla scheda completa: